CN102552992A - Multilayered composite tube, manufacturing method thereof, and application thereof - Google Patents
Multilayered composite tube, manufacturing method thereof, and application thereof Download PDFInfo
- Publication number
- CN102552992A CN102552992A CN2011102832013A CN201110283201A CN102552992A CN 102552992 A CN102552992 A CN 102552992A CN 2011102832013 A CN2011102832013 A CN 2011102832013A CN 201110283201 A CN201110283201 A CN 201110283201A CN 102552992 A CN102552992 A CN 102552992A
- Authority
- CN
- China
- Prior art keywords
- component
- medicine
- tubing
- melt
- multicomponent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a multilayered composite tube, a manufacturing method thereof, and a human endoluminal stent manufactured from the tube. The composite tube at least comprises two layers, which are an inner layer component A and an outer layer component B. The tube can also comprise an interlayer component C. At least one of the component A and the component B is a degradable polymer. The component A comprises a medicine component 1. The outer layer component B comprises a medicine component 2. The component C does not comprise medicine. With a fusion or solution method, the components A, B and C are subject to injection molding by using a special distribution plate, such that the composite multilayered tube is formed. The tube is cut or etched, such that hollowed stent is manufactured. Therefore, customization of functional stent aiming at the treatment of different diseased regions can be realized, such that defects of metal stent used in treating angiostegnosis are overcome.
Description
Technical field
The present invention relates to a kind of MULTILAYER COMPOSITE tubing and manufacturing approach and application, more particularly relate to the human lumen support that this tubing of a kind of usefulness is made, belong to medical instruments field.
Technical background
The interventional medicine engineering is the emerging technology subject that develops rapidly in recent years, is meant the engineering in medicine technology that adopts serial intervention apparatus and material (or being called mis instruments and material) and modernized digital diagnosis and treat equipment to carry out the Clinics and Practices operation." Wicresoft, painless, comfortable " become the medical theory that current people pursue; Become 21 century clinical medicine Development Trend; Thereby Wicresoft gets involved medical treatment as a kind of brand-new operation method; Develop with its swift and violent speed, range of operation has almost been contained subjects such as cardiovascular, cerebrovascular, cancer, surgery, gynecological, hals,Nasen und Ohrenheilkunde.The interventional medicine engineering replaces traditional surgery treatment disease on the one hand, provides a kind of wound less treatment means, makes the reluctant disease of some traditional operations be able to satisfactory solution on the other hand, for extensive patients brings glad tidings.
Intervention apparatus is main with endoluminal stent mainly, and the body lumen that can get involved at present has 3 big types, relates to the most of important tube chambers of human body:
1, cardiovascular and cerebrovascular vessel: coronary artery, entocranial artery;
2, peripheral blood vessel: carotid artery, renal artery, thoracoabdominal aorta, limb artery, vein, bone tremulous pulse;
3, non-vessel lumen: liver, biliary tract, esophagus, trachea, urethra.
Wherein, cardiovascular and cerebrovascular vessel support consumption is maximum in all kinds of tube chambers, also is the highest one type of safety requirements.Intravascular stent is seated to disease sites with tubulose hollow out metal rack through operation blood vessel is carried out effectively support, plays the effect of mediation narrow blood vessel.
Although the intravascular stent art can effectively reduce percutaneous transluminal coronary angioplasty (PTCA) back restenosis rate, along with vascular smooth muscle cell curing, restenosis still can take place in blood vessel.Have the case of 20%-30% that in-stent restenosis can take place, in diabetes, small vessel disease change, long pathological changes, chronic entirely shut pathological changes and bifurcated lesions patient, the in-stent restenosis incidence rate can be up to 30%-70%.
In order to capture this difficult problem of in-stent restenosis; The relevant method of preventing and treating continues to bring out; Wherein (Drug Eluting Stent is the landmark progress of coronary heart disease Jie human therapy DES) to coating stent of medicine, and restenosis rate is selectively being reduced to below 10% in the case.Coating stent of medicine (DES) claim drug releasing stent or bracket for eluting medicament again; As its name suggests; The medicine that will suppress smooth muscle cell proliferation is exactly coated rack outer surface through appropriate method, makes it to form a medicine pond, is close to the diseased region blood vessel.Blood wash away with dissolution under, medicine is constantly from the rack surface eluting, and plays a role in the part.
The coating medicine that is used for coating stent of medicine (DES) comprises rapamycin (Rapamycin) and paclitaxel (Paclitaxel), angiopeptin, Mycophenolic Acid (Mycophenolic Acid), Tracolimus, everolimus Everolimus, ciclosporin A, methyl-RAPM etc.; These medicines can effectively suppress smooth muscle cell proliferation, thereby reduce restenosis in the intravascular stent.
It is reported that the local pathological phenomenon that exists the support endothelialization to postpone after planting people's blood vessel possibly be the major reason of thrombosis in the support in late period.
The support inner surface could be in time again endothelialization also be one of sign of the support success or not of inserting.Endothelialization, promptly Wicresoft's interventional procedure intravascular stent is inserted the process that the back endotheliocyte covers the support inner surface.In case the suitable support of caliber is inserted human vas, the pole of support promptly forms groove on corresponding blood vessel wall, i.e. embeddeding action.The then residual to some extent endotheliocytes in the position that is not embedded between pole, these cells are the multicenter growth gradually, merge each other, have finally covered the entire bracket inwall.The endothelialization process should be accomplished in several weeks.Postpone the ill effect of endothelialization; Relevant with thunderous handkerchief mycin of coating medicine and paclitaxel etc. to the inhibitory action of vascular endothelial cell growth; Be the coating medicine when suppressing smooth muscle cell proliferation, equally also act on endotheliocyte, cause intravascular stent inwall endothelialization to increases slowly.
Good coating support should prevent restenosis, can avoid the especially generation of the interior thrombosis of support in late period of thrombosis in the support again.Probucol (Probucol has another name called probacol), Xi Luota azoles (Cilostazol) etc. are the proof medicines useful to endothelialization, have been used for clinical rehabilitation to sufferer behind the implant frame.
If can will suppress medicine and the medicine of promoting endothelialization speed of the smooth muscle cell proliferation outer wall that is respectively applied for support and inwall just can let the diseased region restore nature state as early as possible behind the implant frame, thereby maximum reduction causes the probability of restenosis.
Patent CN-200710111272.9 " a kind of compound medicament intravascular stent and preparation method thereof " discloses the support that a kind of surfaces externally and internally has the different pharmaceutical coating; Support goes out the coating in aperture or formation hole with holes, surface earlier in surface etch with physics or chemical method; To resist the medicine of smooth muscle cell proliferation and outer surface and the inner surface that special capturing endothelial ancestral cell antibody drug is coated on support respectively then respectively, be hidden in the surface hole defect.
This in fact design with the micropore Tibetan medicine also is found among the patent CN-200610109422.8 " manufacture method of metal support surface micro blind hole drug-loaded layer "; This patented invention human corrosive liquid etching intravascular stent; Impregnated in then in the solvent that contains effective medicine and shake; Make medicine infiltrate through micropore, replace the medicine coating.
It is that simple coating support has been opened up new route that obvious this type is embedded in micropore with medicine, and still regardless of the aperture of the surperficial drug storage that obtains through any approach, diameter all is very small, and owing to factors such as surface tension, medicine is embedded in aperture and is not easy.And medicine is also challenged in the uniformity of rack surface.
More fatal is, in order to guarantee stent support property, the surface etch micropore can only be present in the micron-sized degree of depth of surfaces externally and internally, and the medicine that is embedded in can come off when washed away by external force or blood in a large number.Especially support friction of stress and deformation and implantation process in assembling process will be lost high amount of drug, make and suffer fatal destruction with regard to incomplete drug delivery system originally, and implant frame can not well play the effect of initial setting.
Summary of the invention
One of the object of the invention provides the MULTILAYER COMPOSITE tubing that is used for the inside of human body intraluminal stent.
Two of the object of the invention provides the method for preparing of the MULTILAYER COMPOSITE tubing that is used for the inside of human body intraluminal stent.
These purposes of the present invention and other purposes will come further to embody and set forth through following detailed description and explanation.
The present invention adopts fusion or solution mode with two or more identical or different component polymer, through special distribution plate, is injection molded into compound multi-layer tubes, and then cuts or be etched into the Openworks shape support.Wherein the polymer of every kind of component can add one or more different active drugs respectively in melt or solution, realizes to different lesions position treatment demand customization function property support.
A kind of multicomponent tubing of the present invention, tubing are two-layer inside and outside at least, interior layer component A and outer B component.Interior layer component A can be similar or polymer homolog with outer B component, also can be two kinds of diverse polymer, and A and B are at least a to be degradable polymer.A and B can be a kind of of following polymers or two kinds; The perhaps mixture of following polymers; These polymer include but are not limited to: and polylactic acid (polylacticacid, PLA), L-polylactic acid (polyLlactic acid, PLLA or LPLA), polyglycolic acid/copolymer of poly lactic acid (polyglycolic acid/polylactic acid; PGLA or PLGA), polycaprolactone (polycaprolactone; PCL), polyhydroxybutyrate valerate (polyhydroxylbutyrate valerate, PHBV), polyacetylglutamic acid (polyacetylglutamicacid, PAGA), polyorthoesters (polyorthoesters; POE) and polyethylene glycol oxide/polybutene copolymer (polyethylene oxide/polybutylene terephthalate, PEO/PBTP) etc.Polymer commonly used is PLA, PLLA, PGLA, PCL or their mixture.
A kind of multicomponent tubing that the present invention makes, interior layer component A contains medicine 1, and outer B component contains medicine 2.Medicine 1 can be of the same race or homology medicine with medicine 2, for realizing with a kind of therapeutic purposes; Perhaps medicine 1 can be different kinds or non-homology medicine with medicine 2, is directed against two kinds and even various therapeutic purposes of pathological changes or disease respectively.The molar ratio of component A and B component is 10-90%: 90-10%, and the optimization molar ratio is 40-60%: 60-40%.Medicine 1 is 0.2%-5% with the mass ratio that medicine 2 accounts for total tubing respectively, preferred 1%-2%.Tubing thickness is 0.08-0.40mm, and preferred tubing thickness is 0.10-0.25mm.
More specifically, this multicomponent tubing can be used for the cutting of intravascular stent.When being used for the cutting vessel support, drug 1 waits one or more medicines useful to endothelialization for probucol (Probucol), Xi Luota azoles (Cilostazol) in the component A; One or more can effectively suppress the medicine of smooth muscle cell proliferation to drug 2 for rapamycin (Rapamycin) and paclitaxel (Paclitaxel), angiopeptin, Mycophenolic Acid (Mycophenolic Acid), Tracolimus, everolimus Everolimus, ciclosporin A, methyl-RAPM etc. in the B component.
Under the dual function of internal layer medicine 1 and outer medicine 2, can reach the inhibition smooth muscle cell proliferation, can promote endothelialization again simultaneously.
A kind of multicomponent tubing of the present invention; Between interior layer component A and outer B component, can also there be interlayer C; Interlayer C does not have medicine, adopt degraded or not degradation polymer all can, so component C polymer can for above-mentioned enumerate be used for any of component A and B component.For improving the compatibility, reduce anisotropy in use, component C generally adopts component A or B component (homology) of the same race polymer, perhaps adopts and component A and all good polymer of the B component compatibility.If there is component C, (component A: B component: component C) be 10-60%: 10-60%: 30-80%, the optimization molar ratio is 10-20%: 10-20%: 60-80% to three component molar ratios.
A kind of multicomponent tubing that the present invention makes, its manufacture method is shown in accompanying drawing 1, and key step is following:
With component A and B component fusion respectively (or dissolving), be prepared into melt (or solution), in melt (or solution) preparation, evenly add medicine 1 in the A component, medicine 2 is in the B component.
Melt (or solution) after the fusion fully (or dissolving) is respectively through two further mix homogeneously of static filtering device.
Component A melt (or solution) gets into the distribution plate A channel, and B component melt (or solution) gets into distribution plate B passage.
Component A melt (or solution) and B component melt (or solution) are under pressure advances; Together spray by spray orifice H; Component A melt (or solution) is encapsulated in internal ring by B component melt (or solution) fully in the time of ejection, and under drawing-off, is cooled to multiple tube, shown in accompanying drawing 2 and accompanying drawing 3.
Can be according to demand, revise the distribution plate port number and add channel C, be used for the water conservancy diversion of component C, exist if any interlayer C, can form A in inside, B externally, C is in 2 intermediary sandwich structures, like accompanying drawing 4 with shown in the accompanying drawing 5.
Further, with respect to the temperature margin of medicine, the fusing point of polymer all is higher often, will certainly cause that like this medicine that is added in the melt can lose efficacy or degeneration.To this problem, can use the good solvent of polymers compositions to come dissolve polymer, adopt solution methods to prepare tubing.According to different materials; Can choose but be not limited only to following solvent; Dichloromethane, chloroform, oxolane, acetone, N; Dinethylformamide (DMF), DMAC N,N (DMAC), acetonitrile, isopropyl alcohol, dimethyl sulfoxide (DMSO), hexafluoroisopropanol, Hexafluoro acetone, trifluoroacetic acid etc.Perhaps carry out high polymer copolymerization or blending and modifying, reduce its fusing point to drug resistance scope and get final product to the component A and the B component that need to add medicine.Can take following two kinds of means to the modification of polymer, one of which in the fashionable adding homology of polymer poly low molecular weight monomers, suitably reduces the degree of polymerization.This method implements relative complex; Should consider that the monomeric bio-capacitivity of new adding considers when polymerization, can not bring counter productive again; Like the generation of new polymerizate, the side-product of the beyong contemplation that these are new is to need checking whether to have the biocompatibility that is equal to.Its two, can dystectic polymer and low melting point polymer be joined in proportion mutually, when fusion, carry out even blend, and reach the purpose that reduces the blend fusing point.This method is simple relatively, and control easily.For example in PLLA, add PDLA (gathering L-lactic acid) or PDLLA (gathering racemic lactic acid), can adjust the melt viscosity of blend through the additional proportion of adjustment PDLA or PDLLA.Simultaneously, through component A, B component modification with adjust each component ratio and can adjust drug release rate and scaffold degradation speed.
Adopt the mode that reduces the component fusing point to melt extrude tubing if desired, the existence of component C just seems and more is necessary.Because; It all is to be cost with the sacrificial molecule amount usually that fusing point reduces; Can sacrifice the whole mechanical property of tubing like this, component C does not add any medicine, need not carry out modification to this component; Component C can ensure in component A and B component reduction mechanical property, ensures that tubing still possesses the required mechanical property of implantation.In addition, component C can be used as a barrier, intercepts the drug regimen of characteristic requirement, such as, component A interpolation medicine 1 is even more important in the time of may influencing each other with B component interpolation medicine 2.
A kind of multicomponent tubing that the present invention makes and make internal support for human body lumen with it, it is characterized in that preparation of pipes is good after, need carry out cut or physical chemistry etching to it by design drawing, formation tubulose hollow out support.This support can be held on the corresponding accessory by pressure, is convenient to be released to diseased region through Minimally Invasive Surgery.
With respect to present technology, the present invention has following advantage.Employing is added medicine in the polymer melt (or solution) of fusion (or dissolving) to, and medicine is dispersed in the melt (or solution) fully, can slowly drug release be come out step by step along with the degraded of component A and B component, is used for the affected part treatment.
Moreover support can not produce medicine and come off in advance in assembling and implantation process, can not cause violent release because of blood washes away after the implantation yet.
Support wants must make its diameter reach enough little through producing assembling through getting involved implant into body, could be smoothly through angiography catheter and body lumen.Usually in this process, it is original about 1/2 that the diametric(al) of metallic matrix support can be reduced to, and the polymer-matrix body support frame will reduce to original 1/2 to 1/3, and so big deflection makes support force serious.Collide if rack rod is stressed, touch a little pressure any medication coat that is enough to crush, cause coating to break or peel off.And with medicine disperse fully with the support matrix in, can ignore and possibly hold the holiday that causes because of pressure.
In addition, a kind of multicomponent tubing of the present invention and make internal support for human body lumen with it can shorten present support production procedure, saves spraying medicine and series of steps such as pharmaceutical drying, weighing.When enhancing productivity, reduced uncertain factor because of bringing in the production procedure.
The present invention aims to provide a kind of method that possesses the required tubing of internal support for human body lumen of multiple therapeutic effect and make this tubing and support, to remedy the many disadvantages that commercial stents is used to treat angiostenosis.
In the present invention, if not refer in particular to, it is the unit of weight on basis that all parts, amount are with the gross weight, and all raw materials all can be buied from market.
Below further specify the present invention through specific embodiment, but embodiment only be used for the explanation, can not limit scope of the present invention.
Description of drawings
Fig. 1 is a MULTILAYER COMPOSITE tubing manufacturing process sketch map
Fig. 2 is two component tubing and support cross section sketch map
Fig. 3 is that two component tubing and support cross section sketch map are local
Fig. 4 is three component tubing and support cross section sketch map
Fig. 5 is that three component tubing and support cross section sketch map are local
Specific embodiment
Component A:PCL 500g B component: PCL 500g
Medicine 1: Xi Luota azoles 10g medicine 2: rapamycin 10g
500g component A PCL and 500g B component PCL are melted in screw rod respectively, are prepared into melt, in the melt preparation, evenly add 10g medicine 1 Xi Luota azoles, add 10g medicine 2 rapamycins in the B component in the A component.The B component PCL melt of the component A PCL melt of consolute Xi Luota azoles and complete consolute rapamycin is respectively through two further mix homogeneously of static filtering device fully.
The component A PCL melt that contains the Xi Luota azoles gets into the distribution plate A channel, and the B component PCL melt that contains rapamycin gets into distribution plate B passage.
The component A PCL melt that contains the Xi Luota azoles and the B component PCL melt that contains rapamycin are under pressure advances; Together spray by spray orifice H; The B component PCL melt that the component A PCL melt that ejection the time contains the Xi Luota azoles is contained rapamycin encapsulates in internal ring fully, and under drawing-off, is cooled to the multiple tube that tube wall is 0.12mm.
Use laser cutter to cut into the hollow out support multiple tube, support is done cleaning after, press and to hold on the sacculus of induction system.
Component A:PLGA 500g B component: PLGA 500g component C:PLLA 1000g
Medicine 1: Xi Luota azoles 10g medicine 2: rapamycin 10g
In 500g component A PLGA, 500g B component PLGA and the chloroform of 1000g component C PLLA respectively at capacity; Be prepared into macromolecular solution; In formulations prepared from solutions, evenly add 10g medicine 1 Xi Luota azoles in the A component, add 10g medicine 2 rapamycins in the B component.The component A PLGA solution of complete miscibility Xi Luota azoles, the B component PLGA solution of complete miscibility rapamycin and component C PLLA solution are respectively through three further mix homogeneously of static filtering device.
The component A PLGA solution that contains the Xi Luota azoles gets into the distribution plate A channel, and the B component PLGA solution that contains rapamycin gets into distribution plate B passage, and component C PLLA solution gets into the distribution plate C-channel.
Contain the component A PLGA solution of Xi Luota azoles, the B component PLGA solution that contains rapamycin and component C PLLA solution under pressure advances; Together spray by spray orifice H; The component A PLGA that contains the Xi Luota azoles in the time of ejection separates out the internal layer at composite pipe; The B component PLGA that contains rapamycin separates out the skin at multiple tube, and component C PLLA is cooled to the multiple tube that tube wall is 0.20mm in the centre of component A PLGA and B component under drawing-off.
Use laser cutter to cut into the hollow out support multiple tube, support is done cleaning after, press and to hold on the sacculus of induction system.
Embodiment 3
Component A:PLLA+PDLLA mixture 500g B component: PLLA+PDLLA mixture 500g
Component C:PLLA 2000g
Medicine 1: probucol 10g medicine 2: paclitaxel 10g
500g component A PLLA+PDLLA mixture and 500g B component PLLA+PDLLA mixture and 2000g PLLA are melted in screw rod respectively; Be prepared into melt; In the melt preparation, evenly add 10g medicine 1 probucol in the A component, add 10g medicine 2 paclitaxel elements in the B component.The B component PLLA+PDLLA mixture melt of the component A PLLA+PDLLA mixture melt of consolute probucol and complete consolute paclitaxel and component C PLLA melt are respectively through three further mix homogeneously of static filtering device fully.
The component A PLLA+PDLLA mixture melt that contains probucol gets into the distribution plate A channel, and the B component PLLA+PDLLA mixture melt that contains paclitaxel gets into distribution plate B passage, and component C PLLA melt gets into the distribution plate C-channel.
Contain the component A PLLA+PDLLA mixture melt of probucol, the B component PLLA+PDLLA mixture melt that contains paclitaxel and component C PLLA melt under pressure advances; Together spray by spray orifice H; The component A PLLA+PDLLA mixture that contains probucol in the time of ejection is separated out the internal layer at composite pipe; The B component PLLA+PDLLA mixture that contains paclitaxel is separated out the skin at multiple tube; And component C PLLA is cooled to the multiple tube that tube wall is 0.30mm in the centre of component A and B component under drawing-off.
Use laser cutter to cut into the hollow out support multiple tube, support is done cleaning after, press and to hold on the sacculus of induction system.
Embodiment 4
Component A:PCL 500g B component: PHBV 500g component C:PLGA 1500g
Medicine 1: Xi Luota azoles 10g medicine 2: rapamycin 10g
In 500g component A PCL, 500g B component PHBV and the hexafluoroisopropanol of 1500g component C PLGA respectively at capacity; Be prepared into macromolecular solution; In formulations prepared from solutions, evenly add 10g medicine 1 Xi Luota azoles in the A component, add 10g medicine 2 rapamycins in the B component.The component A PCL solution of complete miscibility Xi Luota azoles, the B component PHBV solution of complete miscibility rapamycin and component C PLGA solution are respectively through three further mix homogeneously of static filtering device.
The component A PCL solution that contains the Xi Luota azoles gets into the distribution plate A channel, and the B component PHBV solution that contains rapamycin gets into distribution plate B passage, and component C PLGA solution gets into the distribution plate C-channel.
Contain the component A PCL solution of Xi Luota azoles, the B component PHBV solution that contains rapamycin and component C PLGA solution under pressure advances; Together spray by spray orifice H; The component A PCL that contains the Xi Luota azoles in the time of ejection separates out the internal layer at composite pipe; The B component PHBV that contains rapamycin separates out the skin at multiple tube, and component C PLGA is cooled to the multiple tube that tube wall is 0.18mm in the centre of component A PCL and B component PHBV under drawing-off.
Use laser cutter to cut into the hollow out support multiple tube, support is done cleaning after, press and to hold on the sacculus of induction system.
Claims (11)
1. multicomponent tubing; It is characterized in that inside and outside tubing at least two-layer; Form by interior layer component A and outer B component; Layer component A can be similar or polymer homolog with outer B component in described, also can be two kinds of diverse polymer, and A and B are at least a to be degradable polymer; Described polymer is a kind of of following polymers or two kinds, perhaps the mixture of following polymers: polylactic acid, L-polylactic acid, polyglycolic acid/copolymer of poly lactic acid, polycaprolactone, polyhydroxybutyrate valerate, polyacetylglutamic acid, polyorthoesters and polyethylene glycol oxide/polybutene copolymer; At least also contain a kind of medicine that can treat the adaptation pathological changes in interior layer component A and the outer B component, interior layer component A contained drug composition medicine 1 contains ingredient medicine 2 with outer B component, and medicine 1 is identical or different characteristic drug component with medicine 2.
2. multicomponent tubing according to claim 1 is characterized in that between interior layer component A and outer B component also having interlayer component C, and interlayer C does not have medicine, adopt degraded or not degradation polymer all can.
3. multicomponent tubing according to claim 1, the molar ratio of layer component A and outer B component is 10-90%: 90-10% in it is characterized in that, and medicine 1 is 0.2%-5% with the mass ratio that medicine 2 accounts for total tubing respectively, and tubing thickness is 0.08-0.40mm.
4. multicomponent tubing according to claim 1, the molar ratio of layer component A and outer B component is 40-60%: 60-40% in it is characterized in that, and medicine 1 is 1%-2% with the mass ratio that medicine 2 accounts for total tubing respectively, and tubing thickness is 0.08-0.40mm.
5. multicomponent tubing according to claim 3 is characterized in that three component molar ratios are 10-60%: 10-60%: 30-80%.
6. multicomponent tubing according to claim 5 is characterized in that three component molar ratios are 10-20%: 10-20%: 60-80%.
7. multicomponent tubing according to claim 1 is characterized in that drug 1 waits one or more medicines useful to endothelialization for probucol or Xi Luota azoles (Cilostazol) in the component A; Drug 2 is one of rapamycin (Rapamycin) and paclitaxel (Paclitaxel), angiopeptin, Mycophenolic Acid (Mycophenolic Acid), Tracolimus, everolimus Everolimus, ciclosporin A in the B component.
8. according to the method for preparing of the described multicomponent tubing of one of claim 1-7, it is characterized in that adopting the fusion mode to prepare the melt of component A and B component earlier, component A contains medicine 1, and B component contains medicine 2; Medicine 1 uniform mixing is in the melt of component A, and medicine 2 uniform mixing are in the melt of B component; Component A gets into distribution plate after through screw rod SA, and the melt of B component gets into distribution plate after through screw rod SB, then gets into composite spray jet head and extrudes, and is drawn into pipe.
9. according to the method for preparing of the described multicomponent tubing of one of claim 1-7, it is characterized in that adopting the fusion mode to prepare the melt of component A and B component earlier, component A contains medicine 1, and B component contains medicine 2; Medicine 1 uniform mixing is in the melt of component A, and medicine 2 uniform mixing are in the melt of B component; Component A gets into distribution plate after through screw rod SA, and the melt of B component gets into distribution plate after through screw rod SB, then gets into composite spray jet head and extrudes, and is drawn into pipe, and the melt of interlayer component C gets into distribution plate after through screw rod SC.
10. according to Claim 8 or the method for preparing of 9 described multicomponent tubing, it is characterized in that method with cut or chemical etching with its cutting or be etched into the hollow out dress, present production equipment easy to use is processed and clinical installation.
11., it is characterized in that this tubing is used for the internal stent as the body lumen disease, like intravascular stent according to the application of the described multicomponent tubing of one of claim 1-7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110283201.3A CN102552992B (en) | 2011-09-22 | 2011-09-22 | Multilayered composite tube, manufacturing method thereof, and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110283201.3A CN102552992B (en) | 2011-09-22 | 2011-09-22 | Multilayered composite tube, manufacturing method thereof, and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552992A true CN102552992A (en) | 2012-07-11 |
| CN102552992B CN102552992B (en) | 2014-06-11 |
Family
ID=46400437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110283201.3A Active CN102552992B (en) | 2011-09-22 | 2011-09-22 | Multilayered composite tube, manufacturing method thereof, and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552992B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148331A (en) * | 2015-07-24 | 2015-12-16 | 山东华安生物科技有限公司 | Method for producing completely biodegradable intravascular stent and produced intravascular stent |
| CN105288831A (en) * | 2014-06-03 | 2016-02-03 | 辽宁省计划生育科学研究院 | Hollow tubular biodegradable medication system and preparation method thereof |
| WO2015164737A3 (en) * | 2014-04-25 | 2016-06-16 | Abbott Cardiovascular Systems Inc. | Methods and devices for treating a bodily lumen with in situ generated structural support |
| CN107970522A (en) * | 2017-11-24 | 2018-05-01 | 黑龙江工程学院 | A kind of degradable metal base subcutaneously carries embedding thing of medicine and preparation method thereof |
| CN108641074A (en) * | 2018-05-23 | 2018-10-12 | 重庆大学 | Biodegradable material and its preparation method and application |
| CN109350770A (en) * | 2018-12-11 | 2019-02-19 | 上海七木医疗器械有限公司 | A kind of preparation method being layered degradation polymer bracket |
| CN109453437A (en) * | 2017-11-20 | 2019-03-12 | 山东省药学科学院 | A kind of enhanced absorbable stent of nanofiber and preparation method thereof |
| CN109498851A (en) * | 2018-12-11 | 2019-03-22 | 上海七木医疗器械有限公司 | A kind of production technology of Wholly-degradable inside drug containing bracket |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087443A1 (en) * | 2002-04-11 | 2003-10-23 | Secant Medical, Inc. | Covering process using electrospinning of very small fibers |
| CN201179222Y (en) * | 2008-02-03 | 2009-01-14 | 吴昊 | Medicament coating bracket |
| CN101361991A (en) * | 2008-09-19 | 2009-02-11 | 华东医院 | Slowly released type antibiotic medical catheter and preparation method thereof |
| CN101623521A (en) * | 2009-08-06 | 2010-01-13 | 四川大学 | Compound soft tube for disposable infusion apparatus and preparation method thereof |
| WO2010121187A2 (en) * | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
| CN101947353A (en) * | 2010-09-26 | 2011-01-19 | 苏州同科生物材料有限公司 | Degradable medical composite conduit containing functional nano coating and preparation method thereof |
| CN102210616A (en) * | 2010-04-09 | 2011-10-12 | 乐普（北京）医疗器械股份有限公司 | Completely degradable polymer medicine elution stent and preparation method thereof |
-
2011
- 2011-09-22 CN CN201110283201.3A patent/CN102552992B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087443A1 (en) * | 2002-04-11 | 2003-10-23 | Secant Medical, Inc. | Covering process using electrospinning of very small fibers |
| CN201179222Y (en) * | 2008-02-03 | 2009-01-14 | 吴昊 | Medicament coating bracket |
| CN101361991A (en) * | 2008-09-19 | 2009-02-11 | 华东医院 | Slowly released type antibiotic medical catheter and preparation method thereof |
| WO2010121187A2 (en) * | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
| CN101623521A (en) * | 2009-08-06 | 2010-01-13 | 四川大学 | Compound soft tube for disposable infusion apparatus and preparation method thereof |
| CN102210616A (en) * | 2010-04-09 | 2011-10-12 | 乐普（北京）医疗器械股份有限公司 | Completely degradable polymer medicine elution stent and preparation method thereof |
| CN101947353A (en) * | 2010-09-26 | 2011-01-19 | 苏州同科生物材料有限公司 | Degradable medical composite conduit containing functional nano coating and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《Biomaterials》 20090124 Sheng Meng等 "The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system" 第2276-2283页 1-11 第30卷, * |
| 《中国组织工程研究与临床康复》 20071223 Shen Li，Ge Junbo "药物洗脱支架的应用现状和展望" 第10404-10408页 1-11 第11卷, 第51期 * |
| SHEN LI，GE JUNBO: ""药物洗脱支架的应用现状和展望"", 《中国组织工程研究与临床康复》 * |
| SHENG MENG等: ""The effect of a layer-by-layer chitosan–heparin coating on the endothelialization and coagulation properties of a coronary stent system"", 《BIOMATERIALS》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164737A3 (en) * | 2014-04-25 | 2016-06-16 | Abbott Cardiovascular Systems Inc. | Methods and devices for treating a bodily lumen with in situ generated structural support |
| CN105288831A (en) * | 2014-06-03 | 2016-02-03 | 辽宁省计划生育科学研究院 | Hollow tubular biodegradable medication system and preparation method thereof |
| CN105288831B (en) * | 2014-06-03 | 2019-11-08 | 辽宁省计划生育科学研究院 | A kind of biodegradation type drug delivery system of hollow tubular and preparation method thereof |
| CN105148331A (en) * | 2015-07-24 | 2015-12-16 | 山东华安生物科技有限公司 | Method for producing completely biodegradable intravascular stent and produced intravascular stent |
| CN105148331B (en) * | 2015-07-24 | 2018-03-30 | 山东华安生物科技有限公司 | A kind of method for producing fully biodegradable intravascular stent and thus obtained intravascular stent |
| CN109453437A (en) * | 2017-11-20 | 2019-03-12 | 山东省药学科学院 | A kind of enhanced absorbable stent of nanofiber and preparation method thereof |
| CN107970522A (en) * | 2017-11-24 | 2018-05-01 | 黑龙江工程学院 | A kind of degradable metal base subcutaneously carries embedding thing of medicine and preparation method thereof |
| CN108641074A (en) * | 2018-05-23 | 2018-10-12 | 重庆大学 | Biodegradable material and its preparation method and application |
| CN108641074B (en) * | 2018-05-23 | 2021-01-29 | 重庆大学 | Biodegradable material and preparation method and application thereof |
| CN109350770A (en) * | 2018-12-11 | 2019-02-19 | 上海七木医疗器械有限公司 | A kind of preparation method being layered degradation polymer bracket |
| CN109498851A (en) * | 2018-12-11 | 2019-03-22 | 上海七木医疗器械有限公司 | A kind of production technology of Wholly-degradable inside drug containing bracket |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552992B (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552992B (en) | Multilayered composite tube, manufacturing method thereof, and application thereof | |
| CN105477690B (en) | A kind of degradable tubing of multilayer, bracket and preparation method thereof | |
| CN103547723B (en) | Implant including adhesive-bonded fabric | |
| CN1649551B (en) | Drug-delivery endovascular stent and method for treating restenosis | |
| US7638156B1 (en) | Apparatus and method for selectively coating a medical article | |
| CN106456348B (en) | Endovascular device and application method can be recycled in Film laminated | |
| EP1829531B1 (en) | Low temperature drying methods for forming drug-containing polymeric compositions | |
| US20020123788A1 (en) | Sheath for a prosthesis and methods of forming the same | |
| US20030072868A1 (en) | Methods of forming a coating for a prosthesis | |
| CN104870028B (en) | Complete absorbable pipe endoluminal and its manufacture method | |
| CN101879102A (en) | Groove carrying-type coating decomposable drug eluting stent | |
| CN106974751A (en) | Rapamycin reservoir eluting stent | |
| JP2007229462A (en) | Implantable item formed by dissolution | |
| DE102008002395A1 (en) | Drug-loaded implant | |
| JP2007222637A (en) | Implantable medical device formed by fusion method | |
| CN107049571A (en) | A kind of vertebral artery stent and preparation method thereof | |
| CN106039425A (en) | Full-degradable vascular stent for vascular disease treatment and production method of full-degradable vascular stent | |
| AU2003266630A1 (en) | Thread for vascular stent and vascular stent using the thread | |
| KR101791892B1 (en) | Drug coating stent manufacturing device and manufacturing method thereof | |
| KR101253284B1 (en) | Method for modifying surface of stent | |
| CN101069660B (en) | Preparing method of biliary-tract carriage carrying about medicine | |
| CN102078229A (en) | Degradable coronary artery scaffold and preparation method thereof | |
| KR102409251B1 (en) | Drug-eluting stent | |
| KR101595267B1 (en) | Consecutive Drug releaseing stent for restenosis and inflammatory regulation and manufacturing method thereof | |
| CN108338989B (en) | Compound anti-restenosis medicine of coronary artery medicine elution bracket and controlled release system thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200630 Address after: No.009, Huihe Avenue, Kouzhen, Laiwu District, Jinan City, Shandong Province Patentee after: SHANDONG HUAAN BIOTECHNOLOGY Co.,Ltd. Address before: 201203. B, room 406, block 456, blue wave road, Shanghai, Pudong Patentee before: SHANGHAI WEITE BIOTECHNOLOGY Co.,Ltd. |